Compare OFIX & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | DRTS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.1M | 607.1M |
| IPO Year | N/A | N/A |
| Metric | OFIX | DRTS |
|---|---|---|
| Price | $13.38 | $7.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $21.50 | $8.00 |
| AVG Volume (30 Days) | 205.9K | ★ 418.4K |
| Earning Date | 02-24-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $818,058,000.00 | N/A |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $5.84 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.31 | N/A |
| 52 Week Low | $10.24 | $2.30 |
| 52 Week High | $20.48 | $7.89 |
| Indicator | OFIX | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 62.38 |
| Support Level | $13.30 | $6.23 |
| Resistance Level | $14.23 | $5.14 |
| Average True Range (ATR) | 0.56 | 0.62 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 5.29 | 71.91 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.